Amgen and Novartis to collaborate in neuroscience field, specifically CNP 520 and migraine drugs AMG 334 and AMG 331

Novartis announced that it has entered into a global collaboration with Amgen to commercialise and develop pioneering neuroscience treatments. The companies will partner in the development and commercialisation of a BACE inhibitor programme in Alzheimer's Disease (AD). Novartis' oral therapy CNP 520 will be the lead molecule and further compounds from both company's pre-clinical BACE inhibitor programmes may be considered as follow-on molecules. The collaboration will also focus on new Amgen drugs in the migraine field, including phase III AMG 334 and phase I AMG 301. For the migraine programme, Novartis will have global co-development rights and commercial rights outside the USA, Canada and Japan.